Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Development of Therapies for Rare Genetic Disorders of GPX4: Roadmap and Opportunities

Version 1 : Received: 3 April 2021 / Approved: 5 April 2021 / Online: 5 April 2021 (11:57:03 CEST)

How to cite: Cheff, D.; Muotri, A.; Stockwell, B.; Schmidt, E.; Ran, Q.; Kartha, R.; Johnson, S.; Mittal, P.; Arnér, E.; Wigby, K.; Hall, M.; Ramesh, S. Development of Therapies for Rare Genetic Disorders of GPX4: Roadmap and Opportunities. Preprints 2021, 2021040105 (doi: 10.20944/preprints202104.0105.v1). Cheff, D.; Muotri, A.; Stockwell, B.; Schmidt, E.; Ran, Q.; Kartha, R.; Johnson, S.; Mittal, P.; Arnér, E.; Wigby, K.; Hall, M.; Ramesh, S. Development of Therapies for Rare Genetic Disorders of GPX4: Roadmap and Opportunities. Preprints 2021, 2021040105 (doi: 10.20944/preprints202104.0105.v1).

Abstract

Background: Extremely rare progressive diseases like Sedaghatian-type Spondylometaphyseal Dysplasia (SSMD) can be neonatally lethal and therefore go undiagnosed or are difficult to treat. Recent sequencing efforts have linked this disease to mutations in GPX4, with consequences in the resulting enzyme, glutathione peroxidase 4. This offers potential diagnostic and therapeutic avenues for those suffering from this disease, though the steps toward these treatments is often convoluted, expensive, and time-consuming. Main body: The CureGPX4 organization was developed to promote awareness of GPX4-related diseases like SSMD, as well as support research that could lead to essential therapeutics for patients. We provide an overview of the 21 published SSMD cases and have compiled additional sequencing data for four previously unpublished individuals to illustrate the genetic component of SSMD, and the role of sequencing data in diagnosis. We outline in detail the steps CureGPX4 has taken to reach milestones of team creation, disease understanding, drug repurposing, and design of future studies. Conclusion: The primary aim of this review is to provide a roadmap for therapy development for rare, ultra-rare, and difficult to diagnose diseases, as well as increase awareness of the genetic component of SSMD. This work will offer a better understanding of GPx4-related diseases, and help guide researchers, clinicians, and patients interested in other rare diseases find a path towards treatments.

Keywords

Sedaghatian-type Spondylometaphyseal Dysplasia; SSMD; glutathione peroxidase 4; GPX4; rare genetic disorder; therapy development; roadmap; ultra-rare disease

Subject

MEDICINE & PHARMACOLOGY, Allergology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.